Gagnon Securities’s Rein Therapeutics RNTX Stock Holding History

Gagnon Securities’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$184K	Hold	229,070	–	–	0.03%	83
2026 Q2	$238K	Sell	229,070 -10,450	-4%	-$12.6K	0.05%	77
2026 Q1	$311K	Sell	239,520 -700	-0.3%	-$868	0.07%	73
2025 Q4	$279K	Buy	240,220 +11,528	+5%	+$15.9K	0.06%	76
2025 Q3	$262K	Buy	228,692 +156,947	+219%	+$199K	0.05%	80
2025 Q2	$100K	Hold	71,745	–	–	0.02%	86
2025 Q1	$127K	Hold	71,745	–	–	0.03%	93
2024 Q4	$165K	Sell	71,745 -16	-0%	-$48	0.03%	87
2024 Q3	$254K	Buy	71,761 +33,784	+89%	+$90.3K	0.05%	78
2024 Q2	$105K	Buy	37,977 +30	+0.1%	+$123	0.02%	90
2024 Q1	$252K	Hold	37,947	–	–	0.06%	77
2023 Q4	$116K	Buy	+37,947	New	+$74K	0.03%	98

Other funds holding RNTX

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

BIOS Capital Management Fort Worth, Texas $34.2M AUM 13.29% 1-Year Est. Return

Prosight Management Dallas, Texas $515M AUM 2.95% 1-Year Est. Return

Senvest Management New York $3.45B AUM 44.97% 1-Year Est. Return

Bleichroeder LP New York $1.02B AUM 33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $798M AUM 22.92% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Texas Capital Bank Wealth Management Services Dallas, Texas $1.94B AUM 19.18% 1-Year Est. Return

Gagnon Securities's RNTX Position: Q3 2026 in Review

Gagnon Securities held its Rein Therapeutics (RNTX) position steady in Q3 2026 at 229,070 shares worth $184K. The position accounts for 0.03% of the portfolio, ranked #83.

Gagnon Securities first reported a position in RNTX in Q4 2023 and has held it in 12 quarters since. The position peaked at $311K in Q1 2026. 47 funds tracked by Wall St. Rank hold RNTX as of Q3 2026.

Gagnon Securities held 229,070 shares of Rein Therapeutics worth $184K as of Q3 2026.
Gagnon Securities left its Rein Therapeutics share count unchanged in Q3 2026.
Rein Therapeutics made up 0.03% of Gagnon Securities's portfolio in Q3 2026, its #83 holding.
Gagnon Securities first reported a position in Rein Therapeutics in Q4 2023 and has held it in 12 quarters since.
Gagnon Securities's Rein Therapeutics position peaked at $311K in Q1 2026.
47 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2026.

Based on Gagnon Securities's 13F filing for Q3 2026, filed 5 Nov 2026.